Search

Public Installation Honors Legacy and Contribution of Biotechnology Industry Pioneer Life-sized sculpture of Henri Termeer Unveiled as Square Centerpiece CAMBRIDGE, Mass. -- The Henri A. Termeer Tribute Committee along with [...]

Author John Hawkins has written a well-researched biography about Termeer's legacy--how he built a global biotech giant, Genzyme, and mentored a new generation of business leaders who continue to relentlessly [...]

CAMBRIDGE, Mass. -- Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointments of Don Bergstrom, M.D., Ph.D. as Executive [...]

- At five years in the extension of two Phase III studies, 71 and 61 percent of patients received no additional treatment after the initial two courses of Lemtrada - [...]

CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new investigational data that suggest slowing of cortical gray matter volume loss (atrophy) with Aubagio([R]) [...]

CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the sixth annual Patient Advocacy Leadership (PAL) Awards. The global PAL Awards [...]

CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase [...]

- In the Phase 4 Teri-PRO study, patients switching to Aubagio from other disease-modifying treatments reported a significant increase in treatment satisfaction - CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty [...]

CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first adult patient has enrolled and been dosed in a pivotal Phase 2/3 [...]

- Supported by findings from a large global survey of RMS patients and care partners, vs.MS provides information and tools aimed at driving better informed care - CAMBRIDGE, Mass. -- [...]

CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that positive new brain volume data from an ongoing clinical study of Lemtrada([R]) (alemtuzumab) will [...]

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/3v53qr/follicular) has announced the addition of the 'Follicular Thyroid Cancer - Pipeline Review, H1 2016' report to their offering. This report provides comprehensive information on [...]

- Stowe Joined by Experts to Address Important MS-Related Lifestyle Issues Raised by the MS Community - CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, [...]

Expression of Hope program, featuring works of art by members of the lysosomal storage disorder community, marks 10 year anniversary CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business [...]

Clinical presentations help advance understanding of lysosomal storage disorders and underscore company's commitment to patients with these rare diseases CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit [...]

Awards recognize collaborative and innovative patient advocacy programs supporting the global lysosomal storage disorder community CAMBRIDGE, Mass. -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced [...]

- In the extension of two Phase III pivotal studies, 68 and 60 percent of Lemtrada-treated patients received no additional Lemtrada in the prior four years - - Consistent effects [...]

- Additional MRI data on brain atrophy from Phase III TEMSO study will be presented at ECTRIMS - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that magnetic resonance [...]

- Initial Findings from Global Survey of People Living with Relapsing Multiple Sclerosis (RMS) and Care Partners to be Shared at ECTRIMS - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, [...]

-Marks First Product Opt-In since Formation of Landmark 2014 Alliance for Global Advancement of RNAi Therapeutics as Genetic Medicines- CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi [...]

SAN DIEGO -- Innovive Inc, the leader in disposable IVC rodent caging, today announced that Stephen Baker has joined the company as Vice President of Business Development. Baker joins Innovive [...]

CAMBRIDGE, Mass. -- Dimension Therapeutics, Inc. ('Dimension' or the 'Company'), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced that it has expanded its [...]

Awards will recognize collaborative and innovative patient advocacy programs aimed at supporting the global lysosomal storage disorder community CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, has launched the fifth annual [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, today announced that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa[R] (vandetanib), a rare disease therapy, indicated for the [...]

Investigational enzyme replacement therapy designed to treat the nonneurological manifestations of ASMD which characterize Niemann-Pick disease type B CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the U.S. [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that data on its relapsing multiple sclerosis treatments, Aubagio([R] ) (teriflunomide) and Lemtrada([R] ) (alemtuzumab), will be featured during the 2015 [...]

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted Fast Track designation for the development of GZ/SAR402671, a new investigational oral [...]

- Approximately 70% of Lemtrada Patients Had Not Received Any Additional Lemtrada Treatment in the Prior Three Years - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced that new magnetic [...]

Program aimed at advancing search for therapies targeting most common mutation of CF BETHESDA, Md. -- Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, [...]

- 30 Presentations Planned On Marketed Products and New Data from Company's MS Pipeline - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that new longer-term data on its [...]

Patients receive free genetic sequencing for muscle weakness SEATTLE -- The free LGMD-diagnosis.org genetic sequencing program, launched in September 2014, has been expanded thanks to a charitable contribution by Genzyme, [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for Cerdelga([R]) (INN: eliglustat), the only oral therapy [...]

- Forum provides platform for discussion on current and future care of patients living with Gaucher disease - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, today announced that the sixth [...]

Treatment with Genzyme's Cerdelga ([R] ) (eliglustat) capsules maintains hematological and organ volume stability in adults with Gaucher disease type 1 previously stabilized with intravenous enzyme replacement therapy CAMBRIDGE, Mass. [...]

FRIENDSWOOD, Texas -- Castle Biosciences, Inc. today announced the appointment of Mara G. Aspinall to its Board of Directors, and the addition of James L. Dunn, Jr. to its senior [...]

- Treatment with Genzyme's Cerdelga[R] (eliglustat) for nine months results in significant improvements in spleen volume, hemoglobin level, liver volume and platelet count compared to placebo - CAMBRIDGE, Mass. -- [...]

Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager's Novel CNS Product Pipeline CAMBRIDGE, Mass. -- Voyager Therapeutics, a gene therapy company developing life-changing treatments for [...]

CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the European Commission (EC) has granted marketing authorization for Cerdelga([R]) (INN: eliglustat) capsules, a first line oral therapy for certain [...]

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the Investors section of the [...]

- Lemtrada now available in the U.S. two weeks post approval - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, today announced that the first U.S. patients have initiated treatment with [...]

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion [...]

CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of [...]

- Approval Establishes Genzyme's MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals - CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the U.S. Food [...]

CAMBRIDGE, Mass. -- InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Ann Merrifield to its Board of Directors. Ms. Merrifield most recently was President and Chief Executive Officer [...]

- Company Plans to Present Initial Phase 2 Results at Meeting in November - - On Track to Initiate Phase 3 Trial by Year End Following Successful Completion of Regulatory [...]

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2014 on [...]

MADISON, Wis. -- Exact Sciences Corp. (Nasdaq:EXAS) today announced its financial results for the quarter ended Sept. 30, 2014. Exact reported total revenues of $0.0 million for the third quarter [...]

SAN ANTONIO -- As the next step in aggressively increasing sales and growing market adoption, iTraumaCare([R]), an early-stage medical device firm focused on developing traumatic injury solutions for first responder, [...]